Rapidly Expanded EBV-Specific T Cells for the Treatment of Refractory EBV Reactivation and EBV-Related Lymphoproliferative Disorders - Scorecard - MDSpire
Advertisement
Rapidly Expanded EBV-Specific T Cells for the Treatment of Refractory EBV Reactivation and EBV-Related Lymphoproliferative Disorders
Clinical Scorecard: Accelerated Development of EBV-Specific T Cells for Managing Refractory EBV Reactivation and EBV-Associated Lymphoproliferative Disorders
At a Glance
Category
Detail
Condition
Refractory Epstein–Barr virus (EBV) reactivation and EBV-associated lymphoproliferative disorders
Key Mechanisms
Adoptive transfer of rapidly expanded EBV-specific virus-specific T cells (VSTs) targeting latent EBV antigens to restore antiviral immunity
Target Population
Immunocompromised patients including hematopoietic stem cell transplant (HCT) recipients, solid organ transplant (SOT) recipients, and nontransplant patients with EBV-positive lymphoma refractory to standard therapies
Care Setting
Specialized transplant and oncology centers with cell therapy manufacturing capabilities
Key Highlights
Rapid expansion of EBV-specific T cells from autologous or allogeneic peripheral blood mononuclear cells using synthetic viral peptides enables timely treatment of refractory EBV disease.
Phase I/II trial showed a 67% overall response rate, with 86% response in transplant recipients, and good safety profile without treatment-related serious adverse events.
EBV-specific VST therapy offers a promising option for patients with limited alternatives due to refractory EBV reactivation or EBV-associated lymphoma, particularly post-transplant lymphoproliferative disorder (PTLD).
Guideline-Based Recommendations
Diagnosis
Identify EBV reactivation or EBV-associated lymphoma in immunocompromised patients, especially transplant recipients.
Confirm refractory disease status after standard therapies including immunosuppression reduction, rituximab, and chemotherapy.
Management
Consider adoptive transfer of EBV-specific virus-specific T cells (VSTs) derived from autologous or allogeneic PBMCs for refractory cases.
Use rapid expansion protocols (8–12 days) with synthetic viral peptides stimulation to generate VSTs targeting EBNA1 and LMP2 antigens.
Maintain immunosuppression adjustments carefully to balance graft rejection risk and immune restoration.
Monitoring & Follow-up
Monitor clinical response and EBV viral load post-VST infusion.
Assess for adverse events related to cell therapy, noting that serious treatment-related events are uncommon.
Follow patients longitudinally for lymphoma remission and immune reconstitution.
Risks
Potential for graft-versus-host disease (GVHD) in allogeneic transplant recipients.
Disease progression in nonresponders despite VST therapy.
Noninfusion-related complications may occur during follow-up.
Patient & Prescribing Data
Nine patients in phase I/II trial plus three single-patient cases including HCT recipients, SOT recipients, and nontransplant lymphoma patients.
VSTs manufactured from healthy donors and patients showed strong EBV-specific reactivity; 67% overall response rate with higher efficacy in transplant recipients; infusions were well tolerated without serious adverse events.
Clinical Best Practices
Use rapid manufacturing techniques such as G-Rex® vessels with IL-4 and IL-7 supplemented media to shorten VST production time.
Target latent EBV antigens EBNA1 and LMP2 to maximize specificity and efficacy.
Employ both autologous and allogeneic PBMC sources depending on patient status and donor availability.
Incorporate VST therapy as part of a multidisciplinary approach including immunosuppression management and standard lymphoma treatments.
One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.
